由于阿尔茨海默病导致轻度认知障碍的成年人在两年处理速度训练后的日常功能结果与对照训练协议相比
Virginia G Wadley1,2,3, Yue Zhang1, Tyler Bull2,4
1Departments of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Journal of Alzheimer's disease : JAD
|June 26, 2025
概括
处理速度训练在轻度认知障碍 (MCI) 或早期阿尔茨海默病 (AD) 患者中没有维持日常功能. 较大的神经退行预测功能下降,无论训练类型.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 认知康复 认知康复 认知康复
背景情况:
- 认知处理速度对于日常活动至关重要,可以通过在轻度认知障碍 (MCI) 患者的有针对性的培训来提高.
- 处理速度训练对维持这一群体日常功能能力的长期影响仍然基本未知.
研究的目的:
- 调查两年的处理速度训练是否可以在患有MCI或非常轻度阿尔茨海默病 (AD) 的人中保持对独立性至关重要的日常功能.
- 为了比较特定的处理速度培训协议与控制培训协议在维持功能能力方面的有效性.
主要方法:
- 一项随机对照试验涉及103名参与者 (90名患有MCI,13名患有非常轻度的AD) 超过两年.
- 对处理速度培训协议与控制培训协议的客观评估,包括实验室和家庭培训.
- 对日常生活工具活动 (IADLs),社区流动性和道路驾驶表现的纵向评估,并对APOE ε4状态和基线神经退行进行调整.
主要成果:
- 在处理速度训练组和对照组之间,IADL功能,驾驶能力或社区流动性的变化没有显著差异.
- 较高的基线神经退行水平与所有测量的功能结果 (p < 0.001) 的较大下降密切相关.
结论:
- 与一般基于计算机的活动相比,处理速度训练在MCI或非常轻度的AD患者的日常功能维护方面没有表现出更高的有效性.
- 基线神经退行是该人群功能衰退的重要预测因素,突出其在疾病进展和功能结果中的关键作用.
相关概念视频
Cognitive Development During Adulthood
303
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
303
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


